Targeting of a platinum-bound sunitinib analog to renal proximal tubular cells

ME (Emmy) M Dolman1, Stefan Harmsen1, Ebel HE Pieters1, Rolf W Sparidans2, Marie Lacombe3, B&aacute;lint Szokol4, L&aacute;szl&oacute; Orfi4, Gy&ouml;rgy K&eacute;ri4, Gert Storm1, Wim E Hennink1, Robbert J Kok11Department of Pharmaceutics, Utrecht Institute f...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Dolman MEM, Harmsen S, Pieters EHE, Sparidans RW, Lacombe M, Szokol B, Őrfi L, K&eacute;ri G, Storm G, Hennink WE, Kok RJ
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/f3607798464b4a16907ee9b6f6541fb2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f3607798464b4a16907ee9b6f6541fb2
record_format	dspace
spelling	oai:doaj.org-article:f3607798464b4a16907ee9b6f6541fb22021-12-02T02:06:52ZTargeting of a platinum-bound sunitinib analog to renal proximal tubular cells1176-91141178-2013https://doaj.org/article/f3607798464b4a16907ee9b6f6541fb22012-01-01T00:00:00Zhttp://www.dovepress.com/targeting-of-a-platinum-bound-sunitinib-analog-to-renal-proximal-tubul-a9156https://doaj.org/toc/1176-9114https://doaj.org/toc/1178-2013ME (Emmy) M Dolman1, Stefan Harmsen1, Ebel HE Pieters1, Rolf W Sparidans2, Marie Lacombe3, B&aacute;lint Szokol4, L&aacute;szl&oacute; Orfi4, Gy&ouml;rgy K&eacute;ri4, Gert Storm1, Wim E Hennink1, Robbert J Kok11Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands; 2Faculty of Science, Department of Pharmaceutical Sciences, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, The Netherlands; 3Kreatech Biotechnology BV, Amsterdam, The Netherlands; 4Vichem Chemie Ltd, Budapest, HungaryBackground: Activated proximal tubular cells play an important role in renal fibrosis. We investigated whether sunitinib and a kidney-targeted conjugate of sunitinib were capable of attenuating fibrogenic events in tubulointerstitial fibrosis.Methods: A kidney-targeted conjugate was prepared by linkage of a sunitinib analog (named 17864) via a platinum-based linker to the kidney-specific carrier lysozyme. Pharmacological activity of 17864-lysozyme was evaluated in human kidney proximal tubular cells (HK-2); the capability of the kidney-directed conjugate to accumulate in the kidneys was studied in mice. Potential antifibrotic effects of a single-dose treatment were evaluated in the unilateral ureteral obstruction (UUO) model in mice.Results: The 17864-lysozyme conjugate and its metabolites strongly inhibited tyrosine kinase activity. Upon intravenous injection, 17864-lysozyme rapidly accumulated in the kidneys and provided sustained renal drug levels for up to 3 days after a single dose. Renal drug level area under the curve was increased 28-fold versus an equimolar dose of sunitinib malate. Daily treatment of UUO mice with a high dose of sunitinib malate (50 mg/kg) resulted in antifibrotic responses, but also induced drug-related toxicity. A single dose of 17864-lysozyme (equivalent to 1.8 mg/kg sunitinib) was safe but showed no antifibrotic effects.Conclusion: Multikinase inhibitors like sunitinib can be of benefit in the treatment of fibrotic diseases, provided that their safety can be improved by strategies as presented in this paper, and sustained renal levels can be achieved.Keywords: drug delivery, sunitinib, fibrosis, platinum linkerDolman MEMHarmsen SPieters EHESparidans RWLacombe MSzokol BŐrfi LK&eacute;ri GStorm GHennink WEKok RJDove Medical PressarticleMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2012, Iss default, Pp 417-433 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Dolman MEM Harmsen S Pieters EHE Sparidans RW Lacombe M Szokol B Őrfi L K&eacute;ri G Storm G Hennink WE Kok RJ Targeting of a platinum-bound sunitinib analog to renal proximal tubular cells
description	ME (Emmy) M Dolman1, Stefan Harmsen1, Ebel HE Pieters1, Rolf W Sparidans2, Marie Lacombe3, B&aacute;lint Szokol4, L&aacute;szl&oacute; Orfi4, Gy&ouml;rgy K&eacute;ri4, Gert Storm1, Wim E Hennink1, Robbert J Kok11Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands; 2Faculty of Science, Department of Pharmaceutical Sciences, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, The Netherlands; 3Kreatech Biotechnology BV, Amsterdam, The Netherlands; 4Vichem Chemie Ltd, Budapest, HungaryBackground: Activated proximal tubular cells play an important role in renal fibrosis. We investigated whether sunitinib and a kidney-targeted conjugate of sunitinib were capable of attenuating fibrogenic events in tubulointerstitial fibrosis.Methods: A kidney-targeted conjugate was prepared by linkage of a sunitinib analog (named 17864) via a platinum-based linker to the kidney-specific carrier lysozyme. Pharmacological activity of 17864-lysozyme was evaluated in human kidney proximal tubular cells (HK-2); the capability of the kidney-directed conjugate to accumulate in the kidneys was studied in mice. Potential antifibrotic effects of a single-dose treatment were evaluated in the unilateral ureteral obstruction (UUO) model in mice.Results: The 17864-lysozyme conjugate and its metabolites strongly inhibited tyrosine kinase activity. Upon intravenous injection, 17864-lysozyme rapidly accumulated in the kidneys and provided sustained renal drug levels for up to 3 days after a single dose. Renal drug level area under the curve was increased 28-fold versus an equimolar dose of sunitinib malate. Daily treatment of UUO mice with a high dose of sunitinib malate (50 mg/kg) resulted in antifibrotic responses, but also induced drug-related toxicity. A single dose of 17864-lysozyme (equivalent to 1.8 mg/kg sunitinib) was safe but showed no antifibrotic effects.Conclusion: Multikinase inhibitors like sunitinib can be of benefit in the treatment of fibrotic diseases, provided that their safety can be improved by strategies as presented in this paper, and sustained renal levels can be achieved.Keywords: drug delivery, sunitinib, fibrosis, platinum linker
format	article
author	Dolman MEM Harmsen S Pieters EHE Sparidans RW Lacombe M Szokol B Őrfi L K&eacute;ri G Storm G Hennink WE Kok RJ
author_facet	Dolman MEM Harmsen S Pieters EHE Sparidans RW Lacombe M Szokol B Őrfi L K&eacute;ri G Storm G Hennink WE Kok RJ
author_sort	Dolman MEM
title	Targeting of a platinum-bound sunitinib analog to renal proximal tubular cells
title_short	Targeting of a platinum-bound sunitinib analog to renal proximal tubular cells
title_full	Targeting of a platinum-bound sunitinib analog to renal proximal tubular cells
title_fullStr	Targeting of a platinum-bound sunitinib analog to renal proximal tubular cells
title_full_unstemmed	Targeting of a platinum-bound sunitinib analog to renal proximal tubular cells
title_sort	targeting of a platinum-bound sunitinib analog to renal proximal tubular cells
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/f3607798464b4a16907ee9b6f6541fb2
work_keys_str_mv	AT dolmanmem targetingofaplatinumboundsunitinibanalogtorenalproximaltubularcells AT harmsens targetingofaplatinumboundsunitinibanalogtorenalproximaltubularcells AT pietersehe targetingofaplatinumboundsunitinibanalogtorenalproximaltubularcells AT sparidansrw targetingofaplatinumboundsunitinibanalogtorenalproximaltubularcells AT lacombem targetingofaplatinumboundsunitinibanalogtorenalproximaltubularcells AT szokolb targetingofaplatinumboundsunitinibanalogtorenalproximaltubularcells AT orfil targetingofaplatinumboundsunitinibanalogtorenalproximaltubularcells AT kampeacuterig targetingofaplatinumboundsunitinibanalogtorenalproximaltubularcells AT stormg targetingofaplatinumboundsunitinibanalogtorenalproximaltubularcells AT henninkwe targetingofaplatinumboundsunitinibanalogtorenalproximaltubularcells AT kokrj targetingofaplatinumboundsunitinibanalogtorenalproximaltubularcells
_version_	1718402747897741312

Targeting of a platinum-bound sunitinib analog to renal proximal tubular cells

Ejemplares similares